FDA Feedback Allows Lytix Biopharma's Melanoma Phase III Trial to Proceed
The U.S. Food and Drug Administration (FDA) has provided feedback that allows Lytix Biopharma's registrational Phase III trial of ruxotemitide to move forward.
Lytix Biopharma ASA, a clinical-stage immuno-oncology company, has received feedback from the U.S. Food and Drug Administration (FDA) that permits its planned registrational Phase III trial of ruxotemitide (LTX-315) to proceed. The trial will investigate ruxotemitide in combination with pembrolizumab for patients with high-risk, resectable melanoma.
The FDA raised no objections to the company's proposed randomized Phase III study design. This trial will compare the combination therapy of neoadjuvant ruxotemitide plus pembrolizumab against pembrolizumab alone. The study is designed to assess the efficacy of the combined treatment regimen before surgery in patients diagnosed with high-risk melanoma.
Event-free survival (EFS) is designated as the primary endpoint for the study. This metric will be used to measure the treatment's success in preventing disease progression or recurrence. The trial aims to gather data supporting the potential benefit of adding ruxotemitide to the existing standard of care.
Ruxotemitide is an investigational drug designed to activate the body's immune system to fight cancer. Lytix Biopharma focuses on developing intratumoral therapies, which are administered directly into the tumor. Previous studies have indicated potential therapeutic activity for ruxotemitide.